Clinical trial NCT00551161 - References

Alzheimer Disease — Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease

Citation(s)

•   Adalsteinsson E, Sullivan EV, Kleinhans N, Spielman DM, Pfefferbaum A
  Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet. 2000 May 13;355(9216):1696-7.
•   Anderson RN, Smith BL
  Deaths: leading causes for 2002. Natl Vital Stat Rep. 2005 Mar 7;53(17):1-89.
•   Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K
  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999 Jun;56(6):673-80.
•   Benton A, Hannay HJ, Varney NR
  Visual perception of line direction in patients with unilateral brain disease. Neurology. 1975 Oct;25(10):907-10.
•   Buschke H, Fuld PA
  Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology. 1974 Nov;24(11):1019-25.
•   Buschke, H
  Selective reminding for analysis of memory and learning. J Verb Learn and Verb Behav 12:543-550, 1975.
•   Chen HS, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, Lipton SA
  Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci. 1992 Nov;12(11):4427-36.
•   Cohen JR, Elvevåg B, Goldberg TE
  Cognitive control and semantics in schizophrenia: an integrated approach. Am J Psychiatry. 2005 Oct;162(10):1969-71.
•   Dixon RM, Bradley KM, Budge MM, Styles P, Smith AD
  Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. Brain. 2002 Oct;125(Pt 10):2332-41.
•   Frederick BD, Lyoo IK, Satlin A, Ahn KH, Kim MJ, Yurgelun-Todd DA, Cohen BM, Renshaw PF
  In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Dec;28(8):1313-22.
•   Hamsher KD, Roberts RJ
  Memory for recent U.S. presidents in patients with cerebral disease. J Clin Exp Neuropsychol. 1985 Feb;7(1):1-13.
•   Hoyert DL, Kung HC, Smith BL
  Deaths: preliminary data for 2003. Natl Vital Stat Rep. 2005 Feb 28;53(15):1-48.
•   Huang W, Alexander GE, Chang L, Shetty HU, Krasuski JS, Rapoport SI, Schapiro MB
  Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study. Neurology. 2001 Aug 28;57(4):626-32.
•   Jessen F, Traeber F, Freymann K, Maier W, Schild HH, Block W
  Treatment monitoring and response prediction with proton MR spectroscopy in AD. Neurology. 2006 Aug 8;67(3):528-30.
•   Keilhoff G, Wolf G
  Memantine prevents quinolinic acid-induced hippocampal damage. Eur J Pharmacol. 1992 Sep 4;219(3):451-4.
•   Lin A, Ross BD, Harris K, Wong W
  Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making. NeuroRx. 2005 Apr;2(2):197-214. Review.
•   Linker G, Mirza N, Manetti G, Meyer M, Putnam KT, Sunderland T
  Fine-needle, negative-pressure lumbar puncture: a safe technique for collecting CSF. Neurology. 2002 Dec 24;59(12):2008-9.
•   Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, Quack G
  Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Brain Res. 2002 Dec 20;958(1):210-21.
•   Modrego PJ, Fayed N, Pina MA
  Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. Am J Psychiatry. 2005 Apr;162(4):667-75.
•   Rose SE, de Zubicaray GI, Wang D, Galloway GJ, Chalk JB, Eagle SC, Semple J, Doddrell DM
  A 1H MRS study of probable Alzheimer's disease and normal aging: implications for longitudinal monitoring of dementia progression. Magn Reson Imaging. 1999 Feb;17(2):291-9.
•   Sunderland T, Wolozin B, Galasko D, Levy J, Dukoff R, Bahro M, Lasser R, Motter R, Lehtimäki T, Seubert P
  Longitudinal stability of CSF tau levels in Alzheimer patients. Biol Psychiatry. 1999 Sep 15;46(6):750-5.
•   Waldman AD, Rai GS
  The relationship between cognitive impairment and in vivo metabolite ratios in patients with clinical Alzheimer's disease and vascular dementia: a proton magnetic resonance spectroscopy study. Neuroradiology. 2003 Aug;45(8):507-12. Epub 2003 Jul 22.

An Open-label Exploratory Study With Memantine: Correlation Between Proton Magnetic Resonance Spectroscopy, Cerebrospinal Fluid Biomarkers, and Cognition in Patients With Mild to Moderate Alzheimer's Disease

Details for clinical trial NCT00551161